期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 124, 期 6, 页码 1129-1138出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2009.11.001
关键词
Autoinflammatory; IL-1; inflammasome
资金
- NIAID NIH HHS [R01 AI052430] Funding Source: Medline
The therapy of autoinflammatory syndromes is an excellent example of the power of translational research. Recent advances in our understanding of the molecular and immunologic basis of this newly identified classification of disease have allowed for the application of novel, effective, targeted treatments with life-changing effects on patients. Although colchicine and TNF-alpha inhibitors are important therapies for specific autoinflammatory syndromes, the novel IL-1-targeted drugs are particularly effective for many of these diseases. Recently, the pharmaceutical industry has adopted a strategy of confirming the efficacy of new targeted drugs in often-ignored patients with orphan diseases, and US Food and Drug Administration policies have allowed for accelerated approval of these drugs, creating a win-win situation for patients and industry. This article reviews the general approach to the therapy of autoinflammatory diseases, focusing on current approved therapies and novel approaches that might be used in the future. (J Allergy Clin Immunoll 2009;124:1129-38.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据